结合外螺旋抗体NDT9513727的补体C5a受体的结构
Nathan Robertson1, Mathieu Rappas1, Andrew S Doré1
1Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, UK.
Nature
|January 5, 2018
概括
针对C5a厌氧素化学受体1 (C5aR1) 的小分子提供了新的治疗潜力. 结构分析显示NDT9513727在受体外结合
科学领域:
- 免疫学
- 药理学
- 结构生物学
背景情况:
- 补体系统,特别是C5a, 驱动着炎症, 并与毒症和神经退行等疾病有关.
- 目前的C5a抗剂面临挑战,包括非目标效应和低生物可用性.
- 针对C5aR1 (CD88) 的小分子抑制剂是有前途的治疗候选药物.
研究的目的:
- 阐明小分子C5aR1抗剂的作用机制.
- 确定C5aR1与逆激动剂NDT9513727的复合结构.
- 了解NDT9513727物种选择性的结构基础.
主要方法:
- 结合NDT9513727的热稳定C5aR1 (C5aR1 StaR) 的X射线晶体.
- 基于结构的小分子-配体相互作用分析.
- 跨物种结合方式的比较.
主要成果:
- 结构显示NDT9513727与C5aR1结合在跨膜螺旋3,4和5之间的外螺旋口袋中.
- 与残留物Trp2135.49的关键相互作用似乎对物种选择性至关重要.
- 通过这种独特的结合模式,NDT9513727充当逆激动剂.
结论:
- NDT9513727的外螺旋结合模式解释了其在C5aR1的反向激应.
- 了解这种相互作用为设计更有选择性和有效的C5aR1抑制剂提供了洞察力.
- 这些结构数据有助于开发补充介导疾病的新疗法.
相关概念视频
Drug-Receptor Interaction: Antagonist
5.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.8K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.4K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.8K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K


